Diabetic Retinopathy Market Size, Share & Trends Report

Diabetic Retinopathy Market (2025 - 2030) Size, Share & Trends Analysis Report By Type (Proliferative Diabetic Retinopathy), By Management (Anti-VEGF, Intraocular Steroid Injection, Laser Surgery, Vitrectomy), By Region And Segment Forecasts

Market Segmentation

Type Outlook (Revenue in USD Million, 2018 - 2030)
- Proliferative Diabetic Retinopathy
- Non-proliferative Diabetic Retinopathy
Management Outlook (Revenue in USD Million, 2018 - 2030)
- Anti-VEGF
- Intraocular Steroid Injection
- Laser Surgery
- Vitrectomy
Regional Outlook (Revenue, USD Million, 2018 - 2030)
- North America
  - North America Type Outlook (Revenue in USD Million, 2018 - 2030)
    - Proliferative Diabetic Retinopathy
    - Non-proliferative Diabetic Retinopathy
  - North America Management Outlook (Revenue in USD Million, 2018 - 2030)
    - Anti-VEGF
    - Intraocular Steroid Injection
    - Laser Surgery
    - Vitrectomy
  - U.S.
    - U.S. Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Proliferative Diabetic Retinopathy
      - Non-proliferative Diabetic Retinopathy
    - U.S. Management Outlook (Revenue in USD Million, 2018 - 2030)
      - Anti-VEGF
      - Intraocular Steroid Injection
      - Laser Surgery
      - Vitrectomy
  - Canada
    - Canada Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Proliferative Diabetic Retinopathy
      - Non-proliferative Diabetic Retinopathy
    - Canada Management Outlook (Revenue in USD Million, 2018 - 2030)
      - Anti-VEGF
      - Intraocular Steroid Injection
      - Laser Surgery
      - Vitrectomy
  - Mexico
    - Mexico Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Proliferative Diabetic Retinopathy
      - Non-proliferative Diabetic Retinopathy
    - Mexico Management Outlook (Revenue in USD Million, 2018 - 2030)
      - Anti-VEGF
      - Intraocular Steroid Injection
      - Laser Surgery
      - Vitrectomy
- Europe
  - Europe Type Outlook (Revenue in USD Million, 2018 - 2030)
    - Proliferative Diabetic Retinopathy
    - Non-proliferative Diabetic Retinopathy
  - Europe Management Outlook (Revenue in USD Million, 2018 - 2030)
    - Anti-VEGF
    - Intraocular Steroid Injection
    - Laser Surgery
    - Vitrectomy
  - Germany
    - Germany Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Proliferative Diabetic Retinopathy
      - Non-proliferative Diabetic Retinopathy
    - Germany Management Outlook (Revenue in USD Million, 2018 - 2030)
      - Anti-VEGF
      - Intraocular Steroid Injection
      - Laser Surgery
      - Vitrectomy
  - UK
    - UK Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Proliferative Diabetic Retinopathy
      - Non-proliferative Diabetic Retinopathy
    - UK Management Outlook (Revenue in USD Million, 2018 - 2030)
      - Anti-VEGF
      - Intraocular Steroid Injection
      - Laser Surgery
      - Vitrectomy
  - France
    - France Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Proliferative Diabetic Retinopathy
      - Non-proliferative Diabetic Retinopathy
    - France Management Outlook (Revenue in USD Million, 2018 - 2030)
      - Anti-VEGF
      - Intraocular Steroid Injection
      - Laser Surgery
      - Vitrectomy
  - Italy
    - Italy Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Proliferative Diabetic Retinopathy
      - Non-proliferative Diabetic Retinopathy
    - Italy Management Outlook (Revenue in USD Million, 2018 - 2030)
      - Anti-VEGF
      - Intraocular Steroid Injection
      - Laser Surgery
      - Vitrectomy
  - Spain
    - Spain Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Proliferative Diabetic Retinopathy
      - Non-proliferative Diabetic Retinopathy
    - Spain Management Outlook (Revenue in USD Million, 2018 - 2030)
      - Anti-VEGF
      - Intraocular Steroid Injection
      - Laser Surgery
      - Vitrectomy
  - Denmark
    - Denmark Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Proliferative Diabetic Retinopathy
      - Non-proliferative Diabetic Retinopathy
    - Denmark Management Outlook (Revenue in USD Million, 2018 - 2030)
      - Anti-VEGF
      - Intraocular Steroid Injection
      - Laser Surgery
      - Vitrectomy
  - Sweden
    - Sweden Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Proliferative Diabetic Retinopathy
      - Non-proliferative Diabetic Retinopathy
    - Sweden Management Outlook (Revenue in USD Million, 2018 - 2030)
      - Anti-VEGF
      - Intraocular Steroid Injection
      - Laser Surgery
      - Vitrectomy
  - Norway
    - Norway Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Proliferative Diabetic Retinopathy
      - Non-proliferative Diabetic Retinopathy
    - Norway Management Outlook (Revenue in USD Million, 2018 - 2030)
      - Anti-VEGF
      - Intraocular Steroid Injection
      - Laser Surgery
      - Vitrectomy
- Asia Pacific
  - Asia Pacific Type Outlook (Revenue in USD Million, 2018 - 2030)
    - Proliferative Diabetic Retinopathy
    - Non-proliferative Diabetic Retinopathy
  - Asia Pacific Management Outlook (Revenue in USD Million, 2018 - 2030)
    - Anti-VEGF
    - Intraocular Steroid Injection
    - Laser Surgery
    - Vitrectomy
  - China
    - China Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Proliferative Diabetic Retinopathy
      - Non-proliferative Diabetic Retinopathy
    - China Management Outlook (Revenue in USD Million, 2018 - 2030)
      - Anti-VEGF
      - Intraocular Steroid Injection
      - Laser Surgery
      - Vitrectomy
  - Japan
    - Japan Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Proliferative Diabetic Retinopathy
      - Non-proliferative Diabetic Retinopathy
    - Japan Management Outlook (Revenue in USD Million, 2018 - 2030)
      - Anti-VEGF
      - Intraocular Steroid Injection
      - Laser Surgery
      - Vitrectomy
  - India
    - India Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Proliferative Diabetic Retinopathy
      - Non-proliferative Diabetic Retinopathy
    - India Management Outlook (Revenue in USD Million, 2018 - 2030)
      - Anti-VEGF
      - Intraocular Steroid Injection
      - Laser Surgery
      - Vitrectomy
  - Thailand
    - Thailand Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Proliferative Diabetic Retinopathy
      - Non-proliferative Diabetic Retinopathy
    - Thailand Management Outlook (Revenue in USD Million, 2018 - 2030)
      - Anti-VEGF
      - Intraocular Steroid Injection
      - Laser Surgery
      - Vitrectomy
  - South Korea
    - South Korea Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Proliferative Diabetic Retinopathy
      - Non-proliferative Diabetic Retinopathy
    - South Korea Management Outlook (Revenue in USD Million, 2018 - 2030)
      - Anti-VEGF
      - Intraocular Steroid Injection
      - Laser Surgery
      - Vitrectomy
  - Australia
    - Australia Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Proliferative Diabetic Retinopathy
      - Non-proliferative Diabetic Retinopathy
    - Australia Management Outlook (Revenue in USD Million, 2018 - 2030)
      - Anti-VEGF
      - Intraocular Steroid Injection
      - Laser Surgery
      - Vitrectomy
- Latin America
  - Latin America Type Outlook (Revenue in USD Million, 2018 - 2030)
    - Proliferative Diabetic Retinopathy
    - Non-proliferative Diabetic Retinopathy
  - Latin America Management Outlook (Revenue in USD Million, 2018 - 2030)
    - Anti-VEGF
    - Intraocular Steroid Injection
    - Laser Surgery
    - Vitrectomy
  - Brazil
    - Brazil Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Proliferative Diabetic Retinopathy
      - Non-proliferative Diabetic Retinopathy
    - Brazil Management Outlook (Revenue in USD Million, 2018 - 2030)
      - Anti-VEGF
      - Intraocular Steroid Injection
      - Laser Surgery
      - Vitrectomy
  - Argentina
    - Argentina Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Proliferative Diabetic Retinopathy
      - Non-proliferative Diabetic Retinopathy
    - Argentina Management Outlook (Revenue in USD Million, 2018 - 2030)
      - Anti-VEGF
      - Intraocular Steroid Injection
      - Laser Surgery
      - Vitrectomy
- Middle East and Africa
  - Middle East and Africa Type Outlook (Revenue in USD Million, 2018 - 2030)
    - Proliferative Diabetic Retinopathy
    - Non-proliferative Diabetic Retinopathy
  - Middle East and Africa Management Outlook (Revenue in USD Million, 2018 - 2030)
    - Anti-VEGF
    - Intraocular Steroid Injection
    - Laser Surgery
    - Vitrectomy
  - South Africa
    - South Africa Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Proliferative Diabetic Retinopathy
      - Non-proliferative Diabetic Retinopathy
    - South Africa Management Outlook (Revenue in USD Million, 2018 - 2030)
      - Anti-VEGF
      - Intraocular Steroid Injection
      - Laser Surgery
      - Vitrectomy
  - Saudi Arabia
    - Saudi Arabia Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Proliferative Diabetic Retinopathy
      - Non-proliferative Diabetic Retinopathy
    - Saudi Arabia Management Outlook (Revenue in USD Million, 2018 - 2030)
      - Anti-VEGF
      - Intraocular Steroid Injection
      - Laser Surgery
      - Vitrectomy
  - UAE
    - UAE Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Proliferative Diabetic Retinopathy
      - Non-proliferative Diabetic Retinopathy
    - UAE Management Outlook (Revenue in USD Million, 2018 - 2030)
      - Anti-VEGF
      - Intraocular Steroid Injection
      - Laser Surgery
      - Vitrectomy
  - Kuwait
    - Kuwait Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Proliferative Diabetic Retinopathy
      - Non-proliferative Diabetic Retinopathy
    - Kuwait Management Outlook (Revenue in USD Million, 2018 - 2030)
      - Anti-VEGF
      - Intraocular Steroid Injection
      - Laser Surgery
      - Vitrectomy

Report content

Qualitative Analysis

Industry overview
Industry trends
Market drivers and restraints
Market size
Growth prospects
Porter’s analysis
PESTEL analysis
Key market opportunities prioritized
Competitive landscape
- Company overview
- Financial performance
- Product benchmarking
- Latest strategic developments